NCT02971501 2026-03-17
Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases
National Cancer Institute (NCI)
Phase 2 Active not recruiting
National Cancer Institute (NCI)
Pfizer
M.D. Anderson Cancer Center
Genentech, Inc.
Intergroupe Francophone de Cancerologie Thoracique
AbbVie
ImmunityBio, Inc.
City of Hope Medical Center
Prestige Biopharma Limited